Laboratory tests at ICU admission | All patients (n = 239) | Non-survivors (n = 147) | Survivors (n = 92) | p value, survivors vs non-survivors |
---|---|---|---|---|
Hemoglobin, g/L | 124.9 ± 17.9 | 124.8 ± 17.3 | 124.9 ± 19.0 | 0.966 |
White blood cell count, × 109/L | 7.9 [5.2–10.7] | 8.2 [5.1–11.0] | 7.2 [5.2–10.4] | 0.444 |
Neutrophil count, × 109/L | 6.9 [4.0–19.7] | 7.2 [4.0–9.7] | 6.5 [4.0–9.3] | 0.485 |
Lymphocytes, × 109/L | 0.6 [0. 5–0.8] | 0.6 [0.4–0.8] | 0.7 [0.50–0.9] | 0.008 |
Lymphocyte count < 1.1 × 109/L† | 219 (91.6%) | 139 (94.6%) | 80 (87.0%) | 0.036 |
Lymphocyte count < 0.55 × 109/L | 103 (43.1%) | 73 (50.0%) | 30 (32.6%) | 0.007 |
Platelets, × 109 /L | 175 [125–219] | 160 [110–206] | 186 [148–232] | < 0.001 |
Platelet count < 125 × 109 /L‡ | 59 (24.7%) | 48 (32.7%) | 11 (12.0%) | < 0.001 |
PT, s | 11.9 ± 1.7 | 12.0 ± 1.8 | 11.6 ± 1.4 | 0.079 |
APTT, s | 29.3 ± 9.0 | 29.3 ± 8.9 | 29.4 ± 10.9 | 0.988 |
Total bilirubin, μmol/L | 12.5 [10.3–16.8] | 13.0 [10.8–18.7] | 11.7 [9.5–15.8] | 0.029 |
ALT, U/L | 36 [22–56] | 35 [21–54] | 39 [26–59] | 0.210 |
AST, U/L | 41 [33–62] | 45 [35–64] | 38 [31–61] | 0.051 |
Serum creatinine, U/L | 72.1 [58–85.3] | 73.2 [59.7–92.5] | 70.2 [54.1–81.8] | 0.018 |
hsTNI, pg/mL | 85.5 [35.5–133.5] | 91.0 [44.0–134.0] | 80.0 [30.0–32.0] | 0.410 |
Myoglobin, ng/mL | 105.0 [54.0–155.0] | 100.0 [54.0–150.0] | 110.5 [56.0–162.5] | 0.454 |
IL-6, pg/mL‖ | 9.1 [6.7–12.0] | 9.1 [7.1–12.9] | 9.1 [6.2–11.7] | 0.385 |
Elevated IL-6 level¶ | 185 (77.4%) | 119 (81.0%) | 66 (71.7%) | 0.068 |
Arterial blood gas analysis* | ||||
pH | 7.46 ± 0.07 | 7.46 ± 0.08 | 7.45 ± 0.05 | 0.496 |
pO2/FiO2, mm Hg | 91.3 [66.6–133.5] | 82.4 [61.6–120.4] | 109.0 [77.5–155.6] | 0.005 |
pCO2, mmHg | 35.1 ± 10.8 | 35.6 ± 12.9 | 34.4 ± 6.0 | 0.477 |
HCO3−, mmol/L | 24.4 ± 4.0 | 24.3 ± 4.4 | 24.5 ± 3.3 | 0.839 |